紫杉醇脂质体和紫杉醇在晚期食管癌治疗中的临床研究  

Clinical study of paclitaxel liposomes and paclitaxel in the treatment of advanced esophageal cancer

作　　者：崔红利[1] 刘海燕[1] 杨均[1] 刘卉[1] 张艳梅[1] 樊丽琳[1] 王军[1] 陈东风[1] 

机构地区：[1]第三军医大学野战外科研究所大坪医院消化内科,重庆400042

出　　处：《重庆医学》2015年第19期2641-2643,共3页Chongqing medicine

摘　　要：目的比较紫杉醇脂质体和紫杉醇治疗晚期食管癌的安全性及临床疗效。方法将该科近3年收治的90例晚期食管癌患者分为2组。紫杉醇脂质体组(试验组)45例给予紫杉醇脂质体80mg/m2静脉滴注,第1、8天;奈达铂75mg/m2静脉滴注,第1天。紫杉醇组(对照组)45例给予紫杉醇80mg/m2,静脉滴注,第1、8天;奈达铂75mg/m2,静脉滴注,第1天。3周为1个周期,化疗2个周期后按WHO标准进行评估近期疗效及不良反应。结果近期疗效方面,紫杉醇脂质体和紫杉醇相比较,差异无统计学意义(P>0.05),但在紫杉醇溶媒产生的过敏反应方面,试验组明显低于对照组,差异有统计学意义(P<0.05)。结论紫杉醇脂质体或紫杉醇联合奈达铂治疗晚期食管癌疗效确切,两种紫杉醇疗效相当,但紫杉醇脂质体的过敏反应明显低于紫杉醇,值得临床推广。Objective To compare the safety and clinical efficacy between paclitaxel liposomes and paclitaxel in patients with advanced esophageal cancer. Methods A total of 90 patients with advanced esophageal cancer were enrolled into this study and were randomly divided into paclitaxel liposomes treatment group（treatment group） and paclitaxel treatment group（control group）. The patients of each group were treated with paclitaxel liposomes or paclitaxel 80 mg/m^2 intravenously on day 1 and 8, and nedaplatin 75 mg/m^2 intravenously on day 1,respectively. After two cycles of chemotherapy,three weeks per period,we evaluated the short term efficacy and adverse reactions according to the WHO standard. Results The short term efficacy between control group and treatment group showed no significance statistically （P〉0.05）. However,the incidence of allergic reactions in the treatment group was significantly lower than control group （P〈0.05）. Conclusion Paclitaxel liposomal or paclitaxel combine with nedaplatin was effective equivalently in the treatment of patients with advanced esophageal cancer. But the allergic reactions of paclitaxel liposomal were lower than paclitaxel. It is worthy of clinical promotion.

关 键 词：食管肿瘤 药物疗法 紫杉醇脂质体 紫杉醇 奈达铂 

分 类 号：R735.1[医药卫生—肿瘤]